Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JJT3 | ISIN: US9216591084 | Ticker-Symbol: VM4
Tradegate
03.05.24
18:38 Uhr
4,380 Euro
-0,140
-3,10 %
1-Jahres-Chart
VANDA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VANDA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5804,74003.05.
4,4404,62003.05.

Aktuelle News zur VANDA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrVanda Pharmaceuticals Inc. - 8-A12B/A, Registration of securities1
FrVanda Pharmaceuticals Inc. - 8-K, Current Report2
25.04.Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer6
24.04.Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?6
23.04.Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex437PETAH TIKVA (dpa-AFX) - The U.S. Supreme Court denied Vanda Pharmaceuticals Inc.'s (VNDA) petition for a writ of certiorari in its HETLIOZ Abbreviated New Drug Application litigation against...
► Artikel lesen
23.04.Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation39WASHINGTON, April 22, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ®...
► Artikel lesen
22.04.US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetlioz1
22.04.US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz1
22.04.US STOCKS AZZ, Vanda Pharma, Matterport4
22.04.Vanda Pharma falls as Supreme Court rejects case over sleep-drug patents1
22.04.US Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents6
18.04.Vanda turns back on hostile takeover bid by CDMO Future Pak4
18.04.Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up1
17.04.Vanda Pharmaceuticals Inc. - 8-A12B, Registration of securities5
17.04.Vanda Pharmaceuticals Inc. - 8-K, Current Report4
17.04.Vanda Pharma rises after rejecting Future Pak's takeover proposal8
17.04.Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share8
17.04.Why Vanda Pharmaceuticals Stock Is Skyrocketing Today7
17.04.Vanda Pharma Rejects Future Pak's Takeover Proposals; Stock Climbs2
17.04.Vanda Pharmaceuticals rejects takeover proposal from Future Pak11
Seite:  Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1